Newamsterdam Pharma Company (NAMS) — Hedge Fund Ownership Q1 2026
NAMS
- Newamsterdam Pharma Company (NAMS) is held by 3 of 84 tracked hedge funds, with Duquesne Family Office (3%) and Maverick Capital (1%) holding the largest stakes, indicating limited hedge fund interest relative to peers.
- The biggest increases in NAMS holdings came from Maverick Capital (+15%), highlighting conviction.
- 1 hedge fund exited NAMS.
- Overall, hedge funds increased exposure to Newamsterdam Pharma Company (NAMS) by +3% vs the prior quarter and +14% vs prior year.
| # | Fund | % of Portfolio † | Shares † | Shares vs Prior Quarter † | Shares vs Prior Year † | Aggregate Value † | Reported Price * | Option |
|---|---|---|---|---|---|---|---|---|
| 1 |
Duquesne Family Office
|
3.35% | 3.1M | — | +283.60% | $98.3M | $32.01 | — |
| 2 |
Maverick Capital Lee Ainslie
|
0.81% | 2.2M | +15.42% | +297.91% | $70.0M | $32.01 | — |
| 3 |
Viking Global Investors Andreas Halvorsen
|
0.38% | 4.2M | — | -39.76% | $134.6M | $32.01 | — |
| — |
Polen Capital Management
|
— | — | EXITED | — | — | — | — |
| 3 | Total | — | 9.5M | +3.06% | +13.59% | $302.8M | — | — |
* Reported price is not an actual purchase or sale price. It is the price as of the last portfolio date.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.